---
title: "JINYU: It is expected that the net profit in the first half of 2025 will decrease by 43.05% to 53.63% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248371037.md"
description: "JINYU expects that its net profit in the first half of 2025 will decrease by 43.05% to 53.63% year-on-year, with a net profit attributable to shareholders of the listed company expected to be between 57 million yuan and 70 million yuan, a decrease of 52.92 million yuan to 65.92 million yuan. The net profit after deducting non-recurring gains and losses is expected to be between 30 million yuan and 44 million yuan, a year-on-year decrease of 59.21% to 72.19%"
datetime: "2025-07-14T08:34:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248371037.md)
  - [en](https://longbridge.com/en/news/248371037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248371037.md)
generator: "portal-rs"
---

# JINYU: It is expected that the net profit in the first half of 2025 will decrease by 43.05% to 53.63% year-on-year

JINYU announced that it expects to achieve a net profit attributable to shareholders of the listed company of between 57 million and 70 million yuan for the first half of 2025, a decrease of between 52.92 million and 65.92 million yuan compared to the same period last year, representing a year-on-year decrease of 43.05% to 53.63%. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be between 30 million and 44 million yuan for the first half of 2025, a decrease of between 63.86 million and 77.86 million yuan compared to the same period last year, representing a year-on-year decrease of 59.21% to 72.19%

### Related Stocks

- [600201.CN](https://longbridge.com/en/quote/600201.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)
- [06:02 ETAnderson & Vreeland Launches Innovative AVantage Liquid Resin Laboratory](https://longbridge.com/en/news/296768422.md)
- [Unitree launches a seven-axis dexterous arm starting at RMB9,900](https://longbridge.com/en/news/296443546.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**